Uni Eropa - Latvi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - meloxicam - oksikāmi - horses; dogs; cattle; cats; pigs; guinea pigs - kaķiem:mazināšanai vieglas līdz vidēji pēcoperācijas sāpes un iekaisumu pēc ķirurģiskas procedūras, e. ortopēdijas un mīksto audu ķirurģija. atvieglotu sāpes un iekaisumu, akūtu un hronisku skeleta-muskuļu sistēmas traucējumi. samazināt pēcoperācijas sāpes pēc ovariohysterectomy un neliels mīksto audu ķirurģija. cattle:for use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs. lietošanai caurejas gadījumā kombinācijā ar perorālo rehidrācijas terapiju, lai samazinātu klīniskās pazīmes teļu vecumā virs viena nedēļa un jauniem, bez laktējošiem liellopiem. pēcoperācijas sāpju mazināšanai pēc teļu atraušanas. papildterapijai akūta mastīta ārstēšanai kombinācijā ar antibiotiku terapiju. dogs:alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. pēcoperācijas sāpju un iekaisuma samazināšana pēc ortopēdisko un mīksto audu operācijas. horses:for use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders. lai atvieglotu sāpes, kas saistītas ar zirgu koliku. pret iekaisumu un sāpju gan akūtu, gan hronisku balsta un kustību aparāta slimības. cūkas: izmantošanai ārpus infekcijas kustību traucējumiem, lai samazinātu simptomus, klibumu un iekaisumu. par atbrīvojumu no pēcoperācijas sāpes, kas saistītas ar nepilngadīgiem mīksto audu operācijas, piemēram, kastrācija. papildterapijai septicēmijas un toksemijas (mastita-metrīta-agalaktijas sindroma) ārstēšanai ar piemērotu antibiotiku terapiju. jūrascūciņas:mazināšanai vieglas līdz vidēji pēcoperācijas sāpes, kas saistītas ar mīksto audu operācijas, piemēram, vīriešu kastrācija.

Uni Eropa - Latvi - EMA (European Medicines Agency)

astrazeneca ab - olaparibs - olnīcu jaunveidojumi - antineoplastiski līdzekļi - olnīcu cancerlynparza ir norādīts kā monotherapy par:apkope ārstēšanai pieaugušiem pacientiem ar progresējošu (figo posmos, iii un iv) brca1/2-mutācijas (dzimumšūnas līnijas un/vai somatisko) augstas kvalitātes epitēlija olnīcu, olvados, vai primāro peritoneālās vēzi, kas ir atbildes reakcija (pilnīgu vai daļēju) pēc pirmās līnijas platīna ķīmijterapiju. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 un 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. pacientiem ir jābūt iepriekš apstrādāts ar anthracycline un taxane gadā (neo)palīgvielu vai metastātiska iestatījumu, ja vien pacientiem nebija piemēroti šiem apstrādes veidiem (skatīt 5. iedaļu. pacientiem ar hormonu receptoru (ap)-pozitīvs krūts vēzis ir arī ir bijuši par to, vai pēc iepriekšējas endokrīnās terapijas, vai būt nepiemērota par endokrīnās terapijas. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.

Uni Eropa - Latvi - EMA (European Medicines Agency)

janssen-cilag international n.v.    - ponesimod - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Uni Eropa - Latvi - EMA (European Medicines Agency)

ceva-phylaxia veterinary biologicals co. ltd - turkey herpes virus, strain rhvt/nd/ibd, expressing the fusion protein of newcastle disease virus and the vp2 protein of infectious bursal disease virus, live recombinant - imunoloģisks aves - embryonated chicken eggs; chicken - for the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs to reduce mortality, clinical signs and lesions caused by newcastle disease virus (ndv) and to reduce virus shedding; to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (ibdv); to reduce mortality, clinical signs and lesions caused by classical marek’s disease virus (mdv).

Uni Eropa - Latvi - EMA (European Medicines Agency)

neuraxpharm pharmaceuticals s.l. - ublituximab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Uni Eropa - Latvi - EMA (European Medicines Agency)

novartis europharm limited - trametinib - melanoma - antineoplastiski līdzekļi - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 un 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. nav maza šūnu plaušu vēzis (nsclc)trametinib kopā ar dabrafenib ir norādīts ārstēšanai pieaugušiem pacientiem ar progresējošu ne-maza šūnu plaušu vēzis ar braf v600 mutācijas.

Uni Eropa - Latvi - EMA (European Medicines Agency)

intervet international b.v. - cell-associated live recombinant turkey herpesvirus (strain hvt/ndv/ilt) expressing the fusion protein of newcastle disease virus and the glycoproteins gd and gi of infectious laryngotracheitis virus - imunoloģisks aves - embryonated chicken eggs; chicken - for active immunisation of one-day-old chicks or embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to reduce mortality, clinical signs and lesions caused by avian infectious laryngotracheitis (ilt) virus and marek’s disease (md) virus.

Uni Eropa - Latvi - EMA (European Medicines Agency)

roche registration gmbh  - risdiplam - muskuļu atrofija, mugurkaula - other drugs for disorders of the musculo-skeletal system - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.

Uni Eropa - Latvi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease virus, serotype 1, strain rn1250; live recombinant turkey herpesvirus, expressing the vp2 protein of infectious bursal disease virus, strain vhvt013-69 - immunologicals for aves, domestic fowl, avian herpes virus (marek's disease) + avian infectious bursal disease virus (gumboro disease) + newcastle disease virus/paramyxovirus - cālis - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus), and to prevent mortality, clinical signs and lesions caused by infectious bursal disease (ibd) virus.

Uni Eropa - Latvi - EMA (European Medicines Agency)

mylan ireland limited - abiraterona acetāts - prostatas audzēji - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.